US2004211491A1PendingUtilityA1
Stent, method for processing stent, and method of stenting a patient
Priority: Mar 9, 2001Filed: May 21, 2004Published: Oct 28, 2004
Est. expiryMar 9, 2021(expired)· nominal 20-yr term from priority
A61L 31/022Y10T29/49034Y10S623/901A61F 2/82A61F 2/86Y10S148/051
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The subject invention relates to a stent with respect to which the occurrence of artifacts in nuclear spin tomography can be reduced or avoided. The subject invention also pertains to the etching of stents, incorporating titanium and/or titanium alloys, that have been processed with tools containing magnetizing components. The subject invention can also be useful for the control of in-stent-restenosis by allowing imaging under nuclear spin tomography to see in-stent-restenosis in the interior of the subject stent.
Claims
exact text as granted — not AI-modified1 - 5 . (canceled).
6 . A stent, comprising:
TIAl3V2.5, wherein the TIAl3V2.5 exhibits a low incidence of artifacts in nuclear spin tomography.
7 . The stent according to claim 1 , wherein the stent consists essentially entirely of TIAl3V2.5.
8 . The stent according to claim 1 , wherein the stent is viewable in nuclear spin tomography.
9 . The stent according to claim 1 , wherein TIAl3V2.5 has the following composition by weight:
up to 0.08% C; up to 0.03% N 2 ; up to 0.15% O 2 ; 2.0% to 3.0% V; 2.5% to 3.5% Al; up to 0.25% Fe; less than 0.015% H 2 ; and the balance Ti.
10 . The stent according to claim 2 , wherein TIAl3V2.5 has the following composition by weight:
up to 0.08% C; up to 0.03% N 2 ; up to 0.15% O 2 ; 2.0% to 3.0% V; 2.5% to 3.5% Al; up to 0.25% Fe; up to 0.015% H 2 ; and the balance Ti.
11 . A stent, comprising:
TIAl6V4, wherein the TIAl6V4 exhibits a low incidence of artifacts in nuclear spin tomography.
12 . The stent according to claim 6 , wherein the stent is expandable with a balloon catheter.
13 . The stent accrediting to claim 6 , wherein the stent consists essentially entirety of TIAl6V4.
14 . The stent according to claim 6 , wherein the TIAl6V4 has the following composition by weight:
up to 0.08% C; up to 0.05% N 2 ; up to 0.2% O 2 ; 3.5% to 4.5% V; 5.5% to 6.75% Al; up to 0.4% Fe; up to 0.015% H 2 ; and the balance Ti.
15 . The stent according to claim 8 , wherein the TIAl6V4 has the following
up to 0.08% C; up to 0.05% N 2 ; up to 0.2% O 2 ; 3.5% to 4.5% V; 5.5% to 6.75% Al; up to 0.4% Fe; up to 0.015% H 2 ; and the balance Ti.Join the waitlist — get patent alerts
Track US2004211491A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.